Summary

Evidence-based AAN/AES guideline on management of an unprovoked first seizure in adults, addressing recurrence risk, the effect of immediate antiepileptic drug (AED) therapy on short- and long-term prognosis, and AED adverse-event rates. Immediate AED treatment reduces 2-year recurrence risk but does not improve long-term seizure remission or quality of life. Decisions should be individualized, weighing recurrence risk factors against AED adverse effects and patient preferences.

Key Recommendations

Inform adults with an unprovoked first seizure that recurrence risk is greatest within the first 2 years (Level A).
Counsel that a prior brain insult (e.g., stroke, trauma) increases recurrence risk (Level A).
Counsel that an EEG with epileptiform abnormalities increases recurrence risk (Level A).
Counsel that a significant brain-imaging abnormality (Level B) or a nocturnal seizure (Level B) increases recurrence risk.
Advise that immediate AED therapy reduces 2-year recurrence risk compared with deferred treatment (Level B) but may not improve quality of life (Level C).
Advise that immediate AED treatment does not improve long-term (>3 years) prognosis for sustained seizure remission (Level B).
Inform patients that AED adverse-event risk ranges 7%–31%, predominantly mild and reversible (Level B).
Base the decision to start immediate AED therapy on individualized risk–benefit assessment incorporating patient preferences.
Consider that recurrence risk approaching that of patients with multiple seizures (per ILAE, ≥60% over 10 years) may justify treating after a first seizure as epilepsy.

Thresholds & Doses

Recurrence risk after unprovoked first seizure: 21%–45% within first 2 years; ~32% at 1 year, ~46% at 5 years.
Prior brain insult: relative rate of recurrence 2.55 (95% CI 1.44–4.51) at 1–5 years.
Epileptiform EEG: relative rate of recurrence 2.16 (95% CI 1.07–4.38) at 1–5 years.
Abnormal brain imaging: HR 2.44 (95% CI 1.09–5.44) at 1–4 years.
Nocturnal seizure: OR 2.1 (95% CI 1.0–4.3) at 1–4 years.
Immediate vs deferred AED treatment: absolute 2-year recurrence risk reduction ~35% (95% CI 23%–46%).
AED adverse-event incidence: 7%–31% (mild, reversible).
After ≥2 unprovoked seizures: recurrence risk 57% at 1 year, 73% at 4 years.
ILAE definition of epilepsy: ≥60% recurrence risk over 10 years after a single unprovoked seizure.

Citations

Recommendations section — Level A/B/C recommendations on recurrence risk factors and AED therapy
Table 1 — Pooled recurrence rates from Class I/II studies
Table 2 — Short-term (1–2 y) recurrence rates: immediate vs deferred AED treatment
Table 3 — 2-year seizure remission rates with immediate vs deferred AED treatment over >3 years
Analysis of Evidence: Risk of seizure recurrence — clinical variables increasing recurrence risk (prior brain insult, epileptiform EEG, imaging abnormality, nocturnal seizure)
Risks of AED treatment section — AE incidence 7%–31%
Clinical Context — ILAE practical clinical definition of epilepsy (≥60% recurrence threshold)